Relation of Colchicine to Total Joint Arthroplasty Among People With Gout in a Population‐Based Cohort Study
Arthritis & Rheumatology · 2026
DOI: 10.1002/art.43441 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Zhiqiang Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Colchicine, Gout, Gout Suppressants, Arthroplasty, Replacement, Knee. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, National Natural Science Foundation of China, the China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Objective
To evaluate the relation of colchicine use to the risk of total joint arthroplasty (TJA) in individuals with gout, the most common form of arthritis for which colchicine is prescribed.
Methods
This new‐user design, time‐stratified, population‐based cohort study used a UK primary care database (2000–2021). We identified participants with gout who were newly prescribed colchicine after their gout diagnosis. Each colchicine initiator was propensity score matched with a noninitiator using one‐year cohort accrual blocks. The effect of colchicine on the risk of TJA was assessed using Cox proportional hazard regression. Analyses were repeated and limited to participants with both gout and knee/hip osteoarthritis (OA).
Results
We identified 31,478 colchicine initiators who were propensity score matched to an equal number of noninitiators (mean age 60 years, mean body mass index 30), with a median follow‐up time of 4.5 years. Colchicine initiators had a 12% lower risk of TJA than noninitiators (hazard ratio [HR] 0.88, 95% confidence interval [CI] 0.81–0.96), which remained similar after additional adjustment for confounders (HR 0.89, 95% CI 0.82–0.97). Colchicine initiators with gout had a 23% lower risk of TJA among those with knee/hip OA (HR 0.77, 95% CI 0.64–0.92) compared with noninitiators (HR 0.77, 95% CI 0.64–0.92).
Conclusion
In this large population‐based cohort of people with gout, colchicine initiation was associated with a modestly lower risk of TJA. Colchicine may offer a long‐term benefit in reducing the risk of joint arthroplasty in individuals with gout and knee or hip OA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Research Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
- Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts.
ORCID-Profile: Zhiqiang Wang, Tuhina Neogi
Förderung
- NIAMS NIH HHS
- National Natural Science Foundation of China
- the China Postdoctoral Science Foundation
- Osteoarthritis Research Society International (OARSI)
- Hong Kong Scholars Program
- Foundation for the National Institutes of Health
Zitieren
APA
Wang, Z., Tilley, S., Peloquin, C., Petrow, E., Clancy, M., & Neogi, T. (2026). Relation of Colchicine to Total Joint Arthroplasty Among People With Gout in a Population‐Based Cohort Study. Arthritis & Rheumatology. https://doi.org/10.1002/art.43441
Vancouver
Wang Z, Tilley S, Peloquin C, Petrow E, Clancy M, Neogi T. Relation of Colchicine to Total Joint Arthroplasty Among People With Gout in a Population‐Based Cohort Study. Arthritis & Rheumatology. 2026. doi:10.1002/art.43441
BibTeX
@article{Wang2026,
author = {Wang, Zhiqiang and Tilley, Sarah and Peloquin, Christine and Petrow, Eva and Clancy, Margaret and Neogi, Tuhina},
title = {Relation of Colchicine to Total Joint Arthroplasty Among People With Gout in a Population‐Based Cohort Study},
journal = {Arthritis & Rheumatology},
year = {2026},
doi = {10.1002/art.43441}
}
EUVIMED